Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 14/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28381838 | 0.86 | MAPT (0.62) | KDM1ANPC1RAB9AMAPTMMP2 | |
| SCHEMBL22010898 | 0.83 | MMP2 (0.47) | KDM1ANPC1RAB9AMAPTMMP2 | |
| SCHEMBL23532178 | 0.83 | KDM1A (0.52) | KDM1ANPC1RAB9AMAPTEDNRA | |
| SCHEMBL10736988 | 0.82 | MMP2 (0.59) | KDM1ANPC1RAB9AMAPTMMP2 | |
| SCHEMBL5584687 | 0.81 | NPC1 (0.65) | KDM1ANPC1RAB9AMAPTMMP2 | |
| SCHEMBL3611742 | 0.81 | MAPT (0.65) | KDM1ANPC1RAB9AMAPTEDNRA | |
| SCHEMBL23532024 | 0.81 | NPC1 (0.73) | KDM1ANPC1RAB9AMAPTEDNRA | |
| SCHEMBL20305366 | 0.80 | EDNRA (0.71) | NPC1RAB9AMAPTMMP2MMP13 | |
| SCHEMBL4109825 | 0.77 | SMN1; SMN2 (0.62) | NPC1RAB9ATP53TSHRSMN1; SMN2 | |
| SCHEMBL15012161 | 0.76 | NPC1 (0.61) | KDM1ANPC1RAB9AMAPTEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473283-B2 | Compounds and their use | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-11-18 | — | — | US | disclosed |
| CN-115151541-B | Novel compounds and uses thereof | 德彪药业国际股份公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| EP-4077324-A1 | NOVEL COMPOUNDS AND THEIR USE | Debiopharm International SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| CN-115151541-A | Novel compound and use thereof | 德彪药业国际股份公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021123372-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | LSS, PGLS, LDHB | KDM1A 124/4885NPC1 2825/4885RAB9A 1365/4885 |
| US-12473283-B2 | Compounds and their use | LSS, PGLS, LDHB | KDM1A 79/4885NPC1 3338/4885RAB9A 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.